ArticleBritish journal of pharmacology2004
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.
Article in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- Genetic ablation of fibroblast activation protein alpha attenuates left ventricular dilation after myocardial infarction.PloS one · 2021Article
- Cellular and Molecular Mechanism of Traditional Chinese Medicine on Ventricular Remodeling.Frontiers in cardiovascular medicine · 2021Review
- MRI with gadofosveset: A potential marker for permeability in myocardial infarction.Atherosclerosis · 2018Article
- Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.Current diabetes reports · 2018Review
- Deletion of Gas2l3 in mice leads to specific defects in cardiomyocyte cytokinesis during development.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Touch-free measurement of body temperature using close-up thermography of the ocular surface.MethodsX · 2016Article
- Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis.PPAR research · 2016Review
- 5-Lipoxygenase facilitates healing after myocardial infarction.Basic research in cardiology · 2013Article
- Exogenous administration of a recombinant variant of TWEAK impairs healing after myocardial infarction by aggravation of inflammation.PloS one · 2013Article
- PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.Journal of lipid research · 2012Review
- Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.PloS one · 2012Article
- The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.Acta pharmacologica Sinica · 2009Article
- Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.Journal of gastroenterology · 2009Article
- Time-Saving Benefits of Intravital Staining.Journal of histotechnology · 2008Article
- Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.Intensive care medicine · 2008Article
- Thiazolidinediones: effects on insulin resistance and the cardiovascular system.British journal of pharmacology · 2008Review
- Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury.The American journal of pathology · 2007Article
- Article
- Role of p38 mitogen-activated protein kinase in cardiac remodelling.British journal of pharmacology · 2007Article
- Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.Circulation · 2006Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Peroxisome proliferator activated receptor gamma (PPARgamma) has been implicated in several cellular pathways assumed to beneficially affect heart failure progression. In contrast, population-based studies demonstrate an increased incidence of heart failure in patients treated with PPARgamma agonists. Therefore, we examined the effect of pioglitazone, a PPARgamma agonist, on chronic left ventricular remodeling after experimental myocardial infarction (MI) in mice. 2. Mice were treated with placebo or pioglitazone (20 mg x kg(-1) by gavage) from week 1 to week 6 after ligation of the left anterior descending artery. Serial transthoracic echocardiography was performed at weeks 1, 3, and 6. 3. Over 6 weeks, there was no difference in mortality (placebo 12%, pioglitazone 10%). Echocardiography showed significant left ventricular dilatation in animals with MI (week 6, end-systolic area, placebo sham 9.6+/-1.3 vs placebo MI 14.4+/-2.5 mm(2)). However, there was no difference between the placebo and pioglitazone groups (week 6, end-systolic area, pioglitazone MI 14.8+/-2.9 mm(2), P=NS vs placebo). 4. Moreover, there were no changes in metabolic parameters, inflammation, and collagen deposition. Endothelial function in the aorta was not changed by PPARgamma activation. 5. In conclusion, PPARgamma activation did not adversely affect left ventricular remodeling and survival in mice with chronic MI. However, we were also not able to identify a protective effect of pioglitazone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.